Avanir neurology news
Sen. Herb Kohl (D-Wis.) and three members of the House of Representatives sent a letter to Avanir requesting information about the price of neurology drug Nuedexta dextromethorphan/quinidine. The letter set a deadline of June 10 for the information, which includes the total cost of trials leading to the approval of Nuedexta and the total cost to manufacture the drug. Last year, FDA approved Nuedexta to treat pseudobulbar affect (PBA) and gave Avanir three years of marketing exclusivity. According to the lawmakers, the biotech set the average sales price of Nuedexta at $600, above the $20 combined cost of the generics dextromethorphan and quinidine before Nuedexta was approved. Nuedexta is a combination of the NMDA receptor antagonist dextromethorphan with quinidine sulfate, a cytochrome P450 2D6 enzyme inhibitor. ...